Inhibitors that target the PI3K/AKT/mTOR Pathway showed clinical benefit in patients with estrogen receptor (ER) positive BC and patients with triple‐negative breast cancer (TNBC).21, 22. This evidence concerns the gene AKT1 and breast cancer.